Phase 2 Oesophageal Cancer Trial, Recruiting NCT05937438 Sponsor: Anhui Provincial Hospital Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 2 Oesophageal Cancer Trial, Recruiting

NCT05937438
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 18 and 75 years old.
  • People who have already had surgery to remove part or all of their oesophagus (the tube connecting the throat to the stomach).
  • People whose tissue sample from surgery confirmed a specific type of cancer called squamous cell carcinoma.
  • People whose cancer was found to be at a stage classified as pIIb, pIII, or pIVa based on what was found during surgery.
  • People who had more than 12 lymph nodes removed and examined during their surgery.
  • People with a good general level of physical functioning, meaning they are fully active or able to carry out light work (confirmed by a doctor using a standard scale called ECOG 0–1).
  • People who are willing and able to sign a consent form to participate.

Who may not be able to join:

  • People younger than 18 or older than 75 years old.
  • People who have not had surgery to remove their oesophagus.
  • People whose cancer is a type other than squamous cell carcinoma.
  • People whose cancer stage was found to be pI, pIIa, or pIVb based on surgical findings.
  • People who had fewer than 12 lymph nodes removed during surgery.
  • People with limited physical functioning (ECOG score of 2 or 3, meaning they have significant difficulty with daily activities).
  • People who have not signed a consent form.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Dong Qian, M.D., The First Affiliated Hospital of USTC

Phone: +86-19156007756

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Anhui Provincial Hospital
Registry
ClinicalTrials.gov
Start date
1 September 2023
Est. completion
30 September 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

1-year disease-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov